Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 457

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 457
---
 cash flows for the next few years and will need additional funding to support our planned operating activities through profitability. We are actively exploring a range of options to raise funds, including strategic partnerships, out -licensing, or divestment of assets of NLS, and other future strategic actions. In June 2025, we completed our most recent private financing round that initially closed in March 2025, in addition to our 2024 financing rounds, debt conversion and forgiveness, vendor buy -outs, and the ongoing Merger opportunity. Our future viability depends on our ability to extend payment terms with third -partycreditors until additional funds have been raised. Going Concern As of December31, 2024, we had an accumulated deficit of approximately $74.4million and we incurred an operating loss for the year ended December31, 2024, of approximately $4.4million. To date, we have dedicated most of our financial resources to achieve and maintain Phase 3 readiness, research and development, clinical studies associated with its ongoing biopharmaceutical business and general and administrative expenses. We have not generated revenues from our activities and have incurred substantial operating losses. As of December31, 2024, our cash and cash equivalents were $1.7million. Our existing cash and cash equivalents and access to existing financing arrangements will not be sufficient to fund operations for a period of one year from the issuance of these consolidated financial statements. We expect to continue to generate operating losses and negative operating cash flows for the next few years and will need additional funding to support its planned operating activities through profitability. We are actively exploring a range of options to raise funds, including strategic partnerships, out -licensing, or divestment of our assets, and other future strategic actions. During October 2024, we completed a private financing round, debt conversions and forgiveness, and various vendor buy -outs. Additionally, on November4, 2024, we entered into the Merger Agreement. Our future viability is dependent on our ability to raise capital for payment of our vendors and to support on -goingoperations. There can be no assurance that such capital will be available within a sufficient period of time, in sufficient amounts or on terms acceptable to us. These conditions raise substantial doubt about our ability to continue as a going concern beyond one year from the date of issuance of our 2024 consolidated financial statements. Since the fiscal year ended December31, 2024, the Company has undertaken a number of actions which have increased its shareholders’ equity,